{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,6]],"date-time":"2026-10-06T23:21:22Z","timestamp":1791328882416,"version":"4.3.1"},"reference-count":14,"publisher":"Wiley","issue":"6","license":[{"start":{"date-parts":[[2017,2,1]],"date-time":"2017-02-01T00:00:00Z","timestamp":1485907200000},"content-version":"tdm","delay-in-days":0,"URL":"http:\/\/doi.wiley.com\/10.1002\/tdm_license_1"},{"start":{"date-parts":[[2017,2,1]],"date-time":"2017-02-01T00:00:00Z","timestamp":1485907200000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/onlinelibrary.wiley.com\/termsAndConditions"}],"funder":[{"DOI":"10.13039\/100004312","name":"Eli Lilly and Company","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100004312","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["The Journal of Clinical Pharmacology"],"published-print":{"date-parts":[[2017,6]]},"DOI":"10.1002\/jcph.865","type":"journal-article","created":{"date-parts":[[2017,2,1]],"date-time":"2017-02-01T09:29:28Z","timestamp":1485941368000},"page":"739-746","source":"Crossref","is-referenced-by-count":13,"title":["Population Pharmacokinetics of LY2623091 in Patients With Hypertension and Chronic Kidney Disease"],"prefix":"10.1002","volume":"57","author":[{"given":"Evan B.","family":"Wang","sequence":"first","affiliation":[{"name":"Eli Lilly and Company; Indianapolis IN, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Archana","family":"Chaudhary","sequence":"additional","affiliation":[{"name":"Eli Lilly and Company; Indianapolis IN, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Timothy H.","family":"Waterhouse","sequence":"additional","affiliation":[{"name":"Eli Lilly and Company; Indianapolis IN, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Gemma L.","family":"Dickinson","sequence":"additional","affiliation":[{"name":"Eli Lilly and Company; Indianapolis IN, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"311","published-online":{"date-parts":[[2017,2,1]]},"reference":[{"issue":"6","key":"10.1002\/jcph.865-BIB0001|jcph865-cit-0001","doi-asserted-by":"crossref","first-page":"1227","DOI":"10.1161\/01.HYP.0000193502.77417.17","article-title":"Mechanisms of mineralocorticoid action","volume":"46","author":"Fuller","year":"2005","journal-title":"Hypertension"},{"issue":"1","key":"10.1002\/jcph.865-BIB0002|jcph865-cit-0002","doi-asserted-by":"crossref","first-page":"15","DOI":"10.1007\/s10741-005-2344-2","article-title":"Mineralocorticoid receptors: distribution and activation","volume":"10","author":"Funder","year":"2005","journal-title":"Heart Fail Rev"},{"issue":"6","key":"10.1002\/jcph.865-BIB0003|jcph865-cit-0003","first-page":"893","article-title":"Mineralocorticoid excess, dietary sodium, and myocardial fibrosis","volume":"120","author":"Brilla","year":"1992","journal-title":"J Lab Clin Med"},{"issue":"6","key":"10.1002\/jcph.865-BIB0004|jcph865-cit-0004","doi-asserted-by":"crossref","first-page":"2578","DOI":"10.1172\/JCI117269","article-title":"Mineralocorticoids, hypertension, and cardiac fibrosis","volume":"93","author":"Young","year":"1994","journal-title":"J Clin Invest"},{"issue":"9","key":"10.1002\/jcph.865-BIB0005|jcph865-cit-0005","doi-asserted-by":"crossref","first-page":"644","DOI":"10.1111\/j.1751-7176.2011.00511.x","article-title":"Aldosterone blockers (mineralocorticoid receptor antagonism) and potassium-sparing diuretics","volume":"13","author":"Epstein","year":"2011","journal-title":"J Clin Hypertens (Greenwich)"},{"issue":"2","key":"10.1002\/jcph.865-BIB0006|jcph865-cit-0006","doi-asserted-by":"crossref","first-page":"286","DOI":"10.1161\/HYPERTENSIONAHA.108.119966","article-title":"Reconsidering the roles of the mineralocorticoid receptor","volume":"53","author":"Funder","year":"2009","journal-title":"Hypertension"},{"issue":"4","key":"10.1002\/jcph.865-BIB0007|jcph865-cit-0007","doi-asserted-by":"crossref","first-page":"420","DOI":"10.1161\/01.CIR.0000153800.09920.40","article-title":"Mineralocorticoid receptor inhibition ameliorates the transition to myocardial failure and decreases oxidative stress and inflammation in mice with chronic pressure overload","volume":"111","author":"Kuster","year":"2005","journal-title":"Circulation"},{"issue":"1","key":"10.1002\/jcph.865-BIB0008|jcph865-cit-0008","doi-asserted-by":"crossref","first-page":"67","DOI":"10.1016\/S1071-9164(03)00578-5","article-title":"Role of a selective aldosterone blocker in mice with chronic heart failure","volume":"10","author":"Wang","year":"2004","journal-title":"J Card Fail"},{"issue":"8","key":"10.1002\/jcph.865-BIB0009|jcph865-cit-0009","doi-asserted-by":"crossref","first-page":"709","DOI":"10.1016\/S0895-7061(02)02957-6","article-title":"Eplerenone, a selective aldosterone blocker, in mild-to-moderate hypertension","volume":"15","author":"Weinberger","year":"2002","journal-title":"Am J Hypertens"},{"issue":"11","key":"10.1002\/jcph.865-BIB0010|jcph865-cit-0010","doi-asserted-by":"crossref","first-page":"912","DOI":"10.1016\/j.amjmed.2006.03.038","article-title":"Aldosterone blockade: an emerging strategy for abrogating progressive renal disease","volume":"119","author":"Epstein","year":"2006","journal-title":"Am J Med"},{"issue":"6","key":"10.1002\/jcph.865-BIB0011|jcph865-cit-0011","doi-asserted-by":"crossref","first-page":"1074","DOI":"10.1161\/CIRCRESAHA.116.303603","article-title":"New approaches in the treatment of hypertension","volume":"116","author":"Oparil","year":"2015","journal-title":"Circ Res"},{"key":"10.1002\/jcph.865-BIB0012|jcph865-cit-0012","volume-title":"NONMEM Users Guide","author":"Beal","year":"2013"},{"issue":"2","key":"10.1002\/jcph.865-BIB0013|jcph865-cit-0013","doi-asserted-by":"crossref","first-page":"143","DOI":"10.1208\/s12248-011-9255-z","article-title":"Prediction-corrected visual predictive checks for diagnosing nonlinear mixed-effects models","volume":"13","author":"Bergstrand","year":"2011","journal-title":"AAPS J"},{"issue":"6","key":"10.1002\/jcph.865-BIB0014|jcph865-cit-0014","doi-asserted-by":"crossref","first-page":"778","DOI":"10.2174\/138920012800840464","article-title":"Sex differences in the clearance of CYP3A4 substrates: exploring possible reasons for the substrate dependency and lack of consensus","volume":"13","author":"Chetty","year":"2012","journal-title":"Curr Drug Metab"}],"container-title":["The Journal of Clinical Pharmacology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.wiley.com\/onlinelibrary\/tdm\/v1\/articles\/10.1002%2Fjcph.865","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/full\/10.1002\/jcph.865","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2022,7,14]],"date-time":"2022-07-14T13:04:07Z","timestamp":1657803847000},"score":1,"resource":{"primary":{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/10.1002\/jcph.865"}},"subtitle":["Journal of Clinical Pharmacology"],"short-title":[],"issued":{"date-parts":[[2017,2,1]]},"references-count":14,"journal-issue":{"issue":"6","published-print":{"date-parts":[[2017,6]]}},"URL":"https:\/\/doi.org\/10.1002\/jcph.865","archive":["Portico"],"relation":{},"ISSN":["0091-2700"],"issn-type":[{"value":"0091-2700","type":"print"}],"subject":[],"published":{"date-parts":[[2017,2,1]]}}}